https://orcid.org/0000-0002-3084-1658
References
- Chen Y, Prothon S, Su H-L, et al. Pharmacokinetics (PK) of a single dose AZD7594 administered intravenously (IV), orally, and inhaled via two dry powder inhalers (DPI) and a pressurized metered-dose inhaler (pMDI). Paper presented at: ERS (European Respiratory Society); 2017; Milan, Italy.
- Hemmerling M, Nilsson S, Edman K, et al. Selective nonsteroidal glucocorticoid receptor modulators for the inhaled treatment of pulmonary diseases. J Med Chem. 2017;60:8591–8605. doi:10.1021/acs.jmedchem.7b01215.28937774
- Chen Y, Prothon S, Aurivillius M, Eriksson UG, Aggarwal A Safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD7594 after single and multiple ascending inhaled doses in healthy male volunteers. Paper presented at: ASCPT (American Society for Clinical Pharmacology & Therapeutics); 2016; San Diego, USA.
- Brown M, Fuhr R, Su H-L, et al. A randomized trial of AZD7594 a novel non-steroidal anti-inflammatory drug in asthma patients. Paper presented at: ERS (European Respiratory Society); 2017; Milan, Italy.
- Brown MN, Fuhr R, Beier J, et al. Efficacy and safety of AZD7594, an inhaled non-steroidal selective glucocorticoid receptor modulator, in patients with asthma: a phase 2a randomized, double blind, placebo-controlled crossover trial. Respir Res. 2019;20(1):37. doi:10.1186/s12931-019-1000-7.30777086
- Myrand SP, Sekiguchi K, Man MZ, et al. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther. 2008;84(3):347–361. doi:10.1038/sj.clpt.610048218231117
- Sahiner UM, Cetinkaya S, Ozmen S, Arslan Z. Evaluation of adrenocortical function in 3–7 aged asthmatic children treated with moderate doses of fluticasone propionate: reliability of dehydroepiandrosterone sulphate as a screening test. Allergol Immunopathol. 2010;39:154–158. doi:10.1016/j.aller.2010.06.005